{"disease":{"id":"bronchial-diseases","name":"bronchial diseases"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06307379","title":"Patient Reported Outcome and Experience Measures for Bronchoscopic Procedures","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Vitaz","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT01264055","title":"Cross-sectional Characterization of Idiopathic Bronchiectasis","phase":"","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04222972","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03688074","title":"Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06272370","title":"Individualizing Treatment for Asthma in Primary Care","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"DARTNet Institute","has_results":true},{"nct_id":"NCT04319705","title":"Anti-viral Effects of Azithromycin in Patients With Asthma and COPD","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT06636487","title":"Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Copenhagen University Hospital, Hvidovre","has_results":false},{"nct_id":"NCT02909452","title":"Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02897778","title":"Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT04644315","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00830427","title":"A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pfizer","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}